Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Generative Replica Exchange: A Flow-Based Framework for Accelerating Replica-Exchange Simulations.

Journal of chemical theory and computation·2026

Same author

Large-Scale Profiling of Kinase Degradation by Using Norbornene-Based Hydrophobic Tag (HyT) Strategy.

Angewandte Chemie (International ed. in English)·2026

Same author

Indel pattern-guided repair mapping reveals genome-wide DNA repair networks in CRISPR/Cas9 editing.

Nucleic acids research·2026

Same author

Discovery of a Potent RXRγ Degrader WCF-598 for the Treatment of Castration-Resistant Prostate Cancer.

Journal of medicinal chemistry·2026

Same author

Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy.

Nature cell biology·2026

Same author

Structure-Based Design of 4-(1-Methyl-1<i>H</i>-indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors.

Journal of medicinal chemistry·2026

Search research articles

Related Experiment Video

Updated: Jan 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Structure-Based Virtual Screening Discovers Potent PLK1 Inhibitors with Anticancer Activity.

Qian Zhang¹, Wenxin Zhu¹, Yi Cai¹

¹School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.

Journal of Chemical Information and Modeling

|January 6, 2026

Summary

Researchers identified potent PLK1 inhibitors for cancer therapy using a computational-experimental approach. Compound BDE30671203 shows high selectivity and induces cancer cell cycle arrest and apoptosis.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

Related Experiment Videos

Last Updated: Jan 13, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening

Published on: May 12, 2017

Area of Science:

Oncology
Pharmacology
Computational Biology

Background:

Polo-like kinase 1 (PLK1) is a critical regulator of cell cycle progression and a promising target for cancer therapy.
Developing selective PLK1 inhibitors is crucial for effective cancer treatment.

Purpose of the Study:

To identify and validate novel, selective PLK1 inhibitors using a combined computational and experimental strategy.
To evaluate the antiproliferative and mechanistic effects of identified inhibitors in cancer cells.

Main Methods:

Utilized a pipeline including kinase scaffold prioritization, structure-based docking, molecular dynamics (MD) simulations.
Performed in vitro biochemical and cellular assays, including antiproliferative, cell cycle arrest, and apoptosis studies.
Conducted kinase selectivity profiling against related kinases like AURKA and AURKB.

Main Results:

Identified BDE30671203 and PB4767006058 with strong binding affinities to PLK1.
BDE30671203 demonstrated potent PLK1 inhibition (IC50 = 2.163 ± 0.401 nM) and significant antiproliferative effects (IC50 < 10 μM) across seven cancer cell lines.
BDE30671203 induced G2/M arrest and apoptosis, downregulated key cell cycle regulators and Bcl-2, and exhibited high selectivity (>450-fold for AURKA, >1200-fold for AURKB).

Conclusions:

The study provides promising chemical starting points for PLK1-targeted cancer drug discovery.
A robust computational-experimental screening strategy for kinase inhibitor discovery was validated.
BDE30671203 represents a highly selective PLK1 inhibitor with therapeutic potential.